StreetInsider.com News Articles

Form SCHEDULE 13D/A Autolus Therapeutics Filed by: PPF Group a.s.

Fri, 28 Aug 2026 21:08:00 -0400

si-local-file:///var/storage/secattach/20260828/26999435.html

Form SCHEDULE 13D/A Autolus Therapeutics Filed by: PPF Group a.s.

Fri, 28 Aug 2026 21:08:00 -0400

si-local-file:///var/storage/secattach/20260828/26999435.html

Form SCHEDULE 13G/A Autolus Therapeutics Filed by: ARMISTICE CAPITAL, LLC

Fri, 14 Aug 2026 10:02:00 -0400

si-local-file:///var/storage/secattach/20260814/26926086.html

Form SCHEDULE 13G/A Autolus Therapeutics Filed by: ARMISTICE CAPITAL, LLC

Fri, 14 Aug 2026 10:02:00 -0400

si-local-file:///var/storage/secattach/20260814/26926086.html

Form 10-Q Autolus Therapeutics For: Jun 30

Tue, 11 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260811/26905875.html

Form 10-Q Autolus Therapeutics For: Jun 30

Tue, 11 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260811/26905875.html

Form 8-K Autolus Therapeutics For: Aug 11

Tue, 11 Aug 2026 07:34:00 -0400

si-local-file:///var/storage/secattach/20260811/26901473.html

Form 8-K Autolus Therapeutics For: Aug 11

Tue, 11 Aug 2026 07:34:00 -0400

si-local-file:///var/storage/secattach/20260811/26901473.html

Autolus Therapeutics (AUTL) Tops Q2 EPS by 8c

Tue, 11 Aug 2026 07:16:31 -0400

Autolus Therapeutics (NASDAQ: AUTL) reported Q2 EPS of ($0.15), $0.08 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $45.69 million versus the consensus estimate of $30.08 million.

For earnings history and earnings-related data on Autolus Therapeutics (AUTL) click here.

Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

Tue, 11 Aug 2026 07:00:00 -0400

Company reports AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $45.7 million in Q2 2026, an increase of 119% year-over-year
FY 2026 net product revenue guidance increased to $140 - $150 million
Gross margin increased in Q2 2026 , driven by growing volumes and cost reduction initiatives
Capital base strengthened through five-year, interest-only credit facility of up to $250 Million with Perceptive Advisors with $75 million funded at close
Obe-cel clinical development programs on track with trial enrollment ongoing in lupus nephritis, pediatric ALL and progressive multiple sclerosis (MS)
Conference call to be held today at 8:30am EDT/1:30pm BST: conference call participants should

Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

Tue, 11 Aug 2026 07:00:00 -0400

Company reports AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $45.7 million in Q2 2026, an increase of 119% year-over-year
FY 2026 net product revenue guidance increased to $140 - $150 million
Gross margin increased in Q2 2026 , driven by growing volumes and cost reduction initiatives
Capital base strengthened through five-year, interest-only credit facility of up to $250 Million with Perceptive Advisors with $75 million funded at close
Obe-cel clinical development programs on track with trial enrollment ongoing in lupus nephritis, pediatric ALL and progressive multiple sclerosis (MS)
Conference call to be held today at 8:30am EDT/1:30pm BST: conference call participants should

Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

Tue, 11 Aug 2026 07:00:00 -0400

Company reports AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $45.7 million in Q2 2026, an increase of 119% year-over-year
FY 2026 net product revenue guidance increased to $140 - $150 million
Gross margin increased in Q2 2026 , driven by growing volumes and cost reduction initiatives
Capital base strengthened through five-year, interest-only credit facility of up to $250 Million with Perceptive Advisors with $75 million funded at close
Obe-cel clinical development programs on track with trial enrollment ongoing in lupus nephritis, pediatric ALL and progressive multiple sclerosis (MS)
Conference call to be held today at 8:30am EDT/1:30pm BST: conference call participants should

Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

Tue, 11 Aug 2026 07:00:00 -0400

Company reports AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $45.7 million in Q2 2026, an increase of 119% year-over-year
FY 2026 net product revenue guidance increased to $140 - $150 million
Gross margin increased in Q2 2026 , driven by growing volumes and cost reduction initiatives
Capital base strengthened through five-year, interest-only credit facility of up to $250 Million with Perceptive Advisors with $75 million funded at close
Obe-cel clinical development programs on track with trial enrollment ongoing in lupus nephritis, pediatric ALL and progressive multiple sclerosis (MS)
Conference call to be held today at 8:30am EDT/1:30pm BST: conference call participants should

Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026

Mon, 03 Aug 2026 16:05:00 -0400

LONDON and GAITHERSBURG, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the Company will release its second quarter 2026 financial results and operational highlights before open of U.S. markets on Tuesday, August 11, 2026.

Management will host a conference call and webcast at 8:30am EDT / 1:30pm BST to discuss the Company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in

Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026

Mon, 03 Aug 2026 16:05:00 -0400

LONDON and GAITHERSBURG, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the Company will release its second quarter 2026 financial results and operational highlights before open of U.S. markets on Tuesday, August 11, 2026.

Management will host a conference call and webcast at 8:30am EDT / 1:30pm BST to discuss the Company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in

Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026

Mon, 03 Aug 2026 16:05:00 -0400

LONDON and GAITHERSBURG, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the Company will release its second quarter 2026 financial results and operational highlights before open of U.S. markets on Tuesday, August 11, 2026.

Management will host a conference call and webcast at 8:30am EDT / 1:30pm BST to discuss the Company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in

Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026

Mon, 03 Aug 2026 16:05:00 -0400

LONDON and GAITHERSBURG, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the Company will release its second quarter 2026 financial results and operational highlights before open of U.S. markets on Tuesday, August 11, 2026.

Management will host a conference call and webcast at 8:30am EDT / 1:30pm BST to discuss the Company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in

Form 8-K Autolus Therapeutics For: Aug 03

Mon, 03 Aug 2026 08:11:00 -0400
si-local-file:///var/storage/secattach/20260803/26854284.html

Form 8-K Autolus Therapeutics For: Aug 03

Mon, 03 Aug 2026 08:11:00 -0400
si-local-file:///var/storage/secattach/20260803/26854284.html

Autolus raises guidance, secures $250M credit facility with Perceptive

Mon, 03 Aug 2026 07:13:27 -0400

Autolus Therapeutics plc (Nasdaq: AUTL) reported preliminary second quarter 2026 net product revenue of approximately $45 million for its therapy AUCATZYL, representing a roughly 70% increase over Q1 2026 and more than 100% compared to Q2 2025, according to a press release from the company.

The company also reported a year-to-date gross margin of approximately 35%, up from a negative gross margin of approximately 20% in the second half of 2025. As a result, Autolus raised its full-year 2026 net product revenue guidance to $140–$150 million, from a prior range of $120–$135 million.

Autolus also announced it has entered into a senior

Autolus raises guidance, secures $250M credit facility with Perceptive

Mon, 03 Aug 2026 07:13:27 -0400

Autolus Therapeutics plc (Nasdaq: AUTL) reported preliminary second quarter 2026 net product revenue of approximately $45 million for its therapy AUCATZYL, representing a roughly 70% increase over Q1 2026 and more than 100% compared to Q2 2025, according to a press release from the company.

The company also reported a year-to-date gross margin of approximately 35%, up from a negative gross margin of approximately 20% in the second half of 2025. As a result, Autolus raised its full-year 2026 net product revenue guidance to $140–$150 million, from a prior range of $120–$135 million.

Autolus also announced it has entered into a senior

Autolus raises guidance, secures $250M credit facility with Perceptive

Mon, 03 Aug 2026 07:13:27 -0400

Autolus Therapeutics plc (Nasdaq: AUTL) reported preliminary second quarter 2026 net product revenue of approximately $45 million for its therapy AUCATZYL, representing a roughly 70% increase over Q1 2026 and more than 100% compared to Q2 2025, according to a press release from the company.

The company also reported a year-to-date gross margin of approximately 35%, up from a negative gross margin of approximately 20% in the second half of 2025. As a result, Autolus raised its full-year 2026 net product revenue guidance to $140–$150 million, from a prior range of $120–$135 million.

Autolus also announced it has entered into a senior

Autolus raises guidance, secures $250M credit facility with Perceptive

Mon, 03 Aug 2026 07:13:27 -0400

Autolus Therapeutics plc (Nasdaq: AUTL) reported preliminary second quarter 2026 net product revenue of approximately $45 million for its therapy AUCATZYL, representing a roughly 70% increase over Q1 2026 and more than 100% compared to Q2 2025, according to a press release from the company.

The company also reported a year-to-date gross margin of approximately 35%, up from a negative gross margin of approximately 20% in the second half of 2025. As a result, Autolus raised its full-year 2026 net product revenue guidance to $140–$150 million, from a prior range of $120–$135 million.

Autolus also announced it has entered into a senior

Autolus raises guidance, secures $250M credit facility with Perceptive

Mon, 03 Aug 2026 07:13:27 -0400

Autolus Therapeutics plc (Nasdaq: AUTL) reported preliminary second quarter 2026 net product revenue of approximately $45 million for its therapy AUCATZYL, representing a roughly 70% increase over Q1 2026 and more than 100% compared to Q2 2025, according to a press release from the company.

The company also reported a year-to-date gross margin of approximately 35%, up from a negative gross margin of approximately 20% in the second half of 2025. As a result, Autolus raised its full-year 2026 net product revenue guidance to $140–$150 million, from a prior range of $120–$135 million.

Autolus also announced it has entered into a senior

Autolus raises guidance, secures $250M credit facility with Perceptive

Mon, 03 Aug 2026 07:13:27 -0400

Autolus Therapeutics plc (Nasdaq: AUTL) reported preliminary second quarter 2026 net product revenue of approximately $45 million for its therapy AUCATZYL, representing a roughly 70% increase over Q1 2026 and more than 100% compared to Q2 2025, according to a press release from the company.

The company also reported a year-to-date gross margin of approximately 35%, up from a negative gross margin of approximately 20% in the second half of 2025. As a result, Autolus raised its full-year 2026 net product revenue guidance to $140–$150 million, from a prior range of $120–$135 million.

Autolus also announced it has entered into a senior